All In Biotech

Drug Trial Radar · NCT05319314

LYL273 for Patients With Relapsed or Refractory mCRC

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

155

Planned (sponsor's estimate)

Start

Aug 1, 2022

Primary completion

Jun 2028

Study completion Jun 2032

Sponsor

Lead sponsor
Lyell Immunopharma, Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • LYL273Drug

    Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation studyTime frame: Infusion (Day 0) to Day 28
  2. Phase 1: Maximum tolerable dose (MTD) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation studyTime frame: Infusion (Day 0) to Day 28
  3. Phase 1: Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation studyTime frame: Infusion (Day 0) to Day 28
  4. Phase 2: Estimate the efficacy of LYL273, as measured by overall response rate (ORR) based on Independent Review Committee (IRC) assessment per Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 criteriaTime frame: Baseline to Month 18

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • University of California San Francisco Medical Center

    San Francisco, California · Recruiting

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • SCRI Oncology Partners and Tristar Centennial Hospital

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.